https://scholars.lib.ntu.edu.tw/handle/123456789/496074
標題: | Use of metformin and risk of kidney cancer in patients with type 2 diabetes | 作者: | CHIN-HSIAO TSENG | 關鍵字: | Diabetes; Epidemiology; Kidney cancer; Metformin; Taiwan | 公開日期: | 2016 | 出版社: | Elsevier Ltd | 卷: | 52 | 起(迄)頁: | 19-25 | 來源出版物: | European Journal of Cancer | 摘要: | Background The anticancer effect of metformin has been reported in the literature but requires additional confirmation in epidemiologic studies. With respect to kidney cancer scarce data are available. This study investigates whether metformin use in patients with type 2 diabetes mellitus (T2DM) might affect kidney cancer risk. Methods The reimbursement database of the National Health Insurance in Taiwan was used. T2DM patients aged ?40 years and newly treated with either metformin (n = 171,753, "ever users of metformin") or other antidiabetic drugs (n = 75,499, "never users of metformin") within 1998-2002 were followed for at least 6 months for kidney cancer until 31 December 2009. The treatment effect was estimated by Cox regression using propensity score weighting by inverse probability of treatment weighting approach. Hazard ratios were estimated for ever versus never users, and for tertiles of cumulative duration of metformin therapy. Results During follow-up, 917 ever users and 824 never users developed kidney cancer, with respective incidence of 80.09 and 190.30 per 100,000 person-years. The hazard ratio (95% confidence intervals) for ever versus never users is 0.279 (0.254-0.307); and is 0.598 (0.535-0.668), 0.279 (0.243-0.321) and 0.104 (0.088-0.124), respectively, for the first, second, and third tertile of cumulative duration of <14.5, 14.5-45.8 and >45.8 months. In subgroup analyses, the lower risk of kidney cancer associated with metformin use is consistently observed in both sexes, and in patients with or without concomitant use of other antidiabetic drugs. Conclusion Metformin use is associated with a decreased risk of kidney cancer in patients with T2DM. ? 2015 Elsevier Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84948447754&doi=10.1016%2fj.ejca.2015.09.027&partnerID=40&md5=3d234089cf1ddbd0b251b1409ac2b388 https://scholars.lib.ntu.edu.tw/handle/123456789/496074 |
ISSN: | 0959-8049 | DOI: | 10.1016/j.ejca.2015.09.027 | SDG/關鍵字: | acarbose; acetylsalicylic acid; angiotensin receptor antagonist; antidiabetic agent; calcium channel blocking agent; clopidogrel; dipeptidyl carboxypeptidase inhibitor; dipyridamole; fibric acid derivative; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; meglitinide; metformin; nonsteroid antiinflammatory agent; pioglitazone; rosiglitazone; sulfonylurea; ticlopidine; antidiabetic agent; metformin; adult; aged; Article; cancer incidence; cancer risk; cohort analysis; data base; disease association; female; follow up; human; kidney cancer; major clinical study; male; middle aged; national health insurance; non insulin dependent diabetes mellitus; priority journal; Taiwan; treatment duration; treatment indication; Diabetes Mellitus, Type 2; factual database; incidence; Kidney Neoplasms; propensity score; proportional hazards model; protection; risk assessment; risk factor; time factor; Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Kidney Neoplasms; Male; Metformin; Middle Aged; Propensity Score; Proportional Hazards Models; Protective Factors; Risk Assessment; Risk Factors; Taiwan; Time Factors |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。